1. Home
  2. GILD vs GOOGM Comparison

GILD vs GOOGM Comparison

Compare GILD & GOOGM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Gilead Sciences Inc.

GILD

Gilead Sciences Inc.

HOLD

Current Price

$135.71

Market Cap

165.0B

Sector

Health Care

ML Signal

HOLD

GOOGM

Alphabet Inc. Depositary Shares representing a 1/20th Interest in a Share of Series A Mandatory Convertible Preferred Stock

N/A

Current Price

$48.96

Market Cap

624.3B

Sector

Technology

ML Signal

N/A

Company Overview

Basic Information
Metric
GILD
GOOGM
Founded
1987
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Computer Software: Programming Data Processing
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
165.0B
624.3B
IPO Year
2003
2015

Fundamental Metrics

Financial Performance
Metric
GILD
GOOGM
Price
$135.71
$48.96
Analyst Decision
Strong Buy
Analyst Count
18
0
Target Price
$148.39
N/A
AVG Volume (30 Days)
6.5M
1.2M
Earning Date
05-07-2026
N/A
Dividend Yield
2.55%
N/A
EPS Growth
1684.21
34.45
EPS
N/A
14.24
Revenue
$24,689,000,000.00
$402,836,000,000.00
Revenue This Year
$4.68
N/A
Revenue Next Year
$6.04
N/A
P/E Ratio
N/A
$3.45
Revenue Growth
9.98
15.09
52 Week Low
$108.46
$46.24
52 Week High
$157.29
$53.13

Technical Indicators

Market Signals
Indicator
GILD
GOOGM
Relative Strength Index (RSI) 53.39 46.90
Support Level $128.15 $48.45
Resistance Level $138.40 $52.44
Average True Range (ATR) 3.70 1.08
MACD 0.16 -0.01
Stochastic Oscillator 56.41 40.57

Price Performance

Historical Comparison
GILD
GOOGM

About GILD Gilead Sciences Inc.

Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).

Share on Social Networks: